A

Amolyt Pharma

42 employees

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Therapeutic Peptides
Hypoparathyroidism
Metabolic Disease
Wellness
Medical
Pharmaceutical
Endocrine Disease
Endocrinology
Rare Disease

Date founded

2015

Funding rounds raised

Total raised

$137M

from 27 investors over 27 rounds

A

Amolyt Pharma raised $137M on January 6, 2023

Investors: Tekla Capital Management, Intermediate Capital Group (ICG), OrbiMed Advisors, Sofinnova Partners, Sectoral Asset Management and Pontifax Venture Capital

A

Amolyt Pharma raised $80M on September 16, 2021

Investors: OrbiMed Advisors, Sectoral Asset Management, SHAM, Eurazeo, EQT Life Sciences and Pontifax Venture Capital

A

Amolyt Pharma raised undisclosed on August 1, 2020

Investors: Eurazeo

A

Amolyt Pharma raised $75M on July 31, 2019

Investors: Partners HealthCare, Pontifax Venture Capital, EQT Life Sciences, OrbiMed Advisors and SHAM

A

Amolyt Pharma raised $1.9M on March 17, 2015

Investors: Rhône-Alpes Création, SHAM, Sofimacpartners and initiative OCTALFA

A

Amolyt Pharma raised $4.1M on June 4, 2012

Investors: SHAM and initiative OCTALFA

A

Amolyt Pharma raised $4.3M on September 1, 2009

Investors: SHAM and initiative OCTALFA

A

Amolyt Pharma raised $1.7M on May 6, 2008

Investors: initiative OCTALFA

FAQ